10 Nov
2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading pharma IP deal-maker David MacNaughtan of Sagard Healthcare Royalty Partners about his new fund, the growth of the royalty monetisation market and what it takes to strike successful agreements in this area.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth